Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for cancer treatment. Founded in 2007, the company has made significant strides in the oncology sector, particularly with its lead product, onvansertib, which targets specific cancer pathways to enhance treatment efficacy. With a strong presence in major operational regions, Cardiff Oncology is dedicated to advancing precision medicine and improving patient outcomes. The company has garnered attention for its unique approach to targeting KRAS mutations, positioning itself as a leader in the competitive oncology landscape. Notable achievements include successful clinical trials that underscore the potential of its therapies, solidifying Cardiff Oncology's reputation as a key player in the fight against cancer.
DitchCarbon Score
How does Cardiff Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cardiff Oncology, Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cardiff Oncology, Inc.'s reported carbon emissions
Cardiff Oncology, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that Cardiff Oncology may not yet have established a comprehensive framework for addressing its carbon footprint or climate impact. In the context of the biotechnology industry, many companies are increasingly adopting science-based targets and sustainability initiatives to mitigate climate change. However, without specific commitments or emissions data, it is unclear how Cardiff Oncology aligns with these industry trends. As the company progresses, it may consider developing measurable climate strategies to enhance its environmental responsibility and transparency.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cardiff Oncology, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
